Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 16,865,642	$ 26,043,897
Licensing, contracts and grants receivable	130,742	138,889
Research and development incentives receivable	100,372	103,832
Prepaid expenses and other current assets	396,355	282,903
Total current assets	17,493,111	26,569,521
Security deposit	22,777	22,777
Office furniture and equipment, net of accumulated depreciation of $111,742 and $167,848	21,505	22,220
Deferred issuance cost	20,266	20,266
Right-of-use lease assets	367,375	106,155
Research and development incentives receivable	22,339	121,238
Other assets		7,750
Total assets	17,947,373	26,869,927
Current liabilities:
Accounts payable	4,164,627	2,925,544
Accrued expenses	2,235,451	2,956,545
Accrued compensation	59,790	302,936
Lease liabilities - current	106,165	106,151
Convertible debt, current	3,000,000
Deferred revenue, current	100,000
Total current liabilities	9,666,033	6,291,176
Non-current liabilities:
Convertible debt, net of current portion and debt discount of $112,779 and $143,847	6,887,221	9,856,153
Lease liabilities, net of current portion	262,117
Deferred revenue, net of current portion	100,000
Total liabilities	16,915,371	16,147,329
Commitments and contingencies
Shareholders' equity:
Preferred stock, 350,000 shares authorized; none issued or outstanding
Common stock, $.001 par value; 75,000,000 shares authorized; 43,105,191 shares and 42,873,445 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	43,105	42,873
Additional paid-in capital	216,773,316	216,402,890
Accumulated other comprehensive income	25,472	41,942
Accumulated deficit	(215,809,891)	(205,765,107)
Total shareholders' equity	1,032,002	10,722,598
Total liabilities and shareholders' equity	$ 17,947,373	$ 26,869,927